Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET: SZN-8141 in Diabetic Macular Edema
NCT07817121Phase 1Not yet recruiting
- Sponsor
- Surrozen
- Start
- Oct 2026
- Primary completion
- Aug 2027
01
Overview
Phase 1, open-label trial of SZN-8141 in diabetic macular edema (DME) (3 arms), sponsored by Surrozen. Primary endpoint: Treatment-Emergent Adverse Events at 12 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SZN-8141
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07817121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817121.